Final Thoughts on Type 1 Diabetes: Innovations, Challenges and the Road Ahead
A panelist discusses how the adoption of C-peptide preservation as a critical end point in clinical trials represents a paradigm shift in type 1 diabetes (T1D) research, moving beyond glucose control alone to focus on disease-modifying therapies that can maintain endogenous insulin production and potentially alter the fundamental course of the disease.
Video content above is prompted by the following:
- Many emerging therapies are using C-peptide levels as an end point for assessing efficacy. How does this shift impact treatment strategies and clinical research in T1D?
- If there is one key message you would like health care decision-makers to take away from this discussion regarding T1D, what would it be?
- To close our interview, what are some promising avenues for future research and innovation in the field of T1D? What are you most excited about in the future?
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024
October 18th 2024Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.
Read More
